PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
-95.21%
Both companies show declining revenue. Martin Whitman would check for industry-wide issues.
31.39%
Cost growth above 1.5x AGEN's 9.30%. Michael Burry would check for structural cost disadvantages.
-116.81%
Both companies show declining gross profit. Martin Whitman would check industry conditions.
-451.18%
Both companies show margin pressure. Martin Whitman would check industry conditions.
6.71%
R&D growth while AGEN reduces spending. John Neff would investigate strategic advantage.
86.34%
G&A growth while AGEN reduces overhead. John Neff would investigate operational differences.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
29.34%
Operating expenses growth while AGEN reduces costs. John Neff would investigate differences.
29.34%
Total costs growth above 1.5x AGEN's 6.39%. Michael Burry would check for inefficiency.
-100.00%
Both companies reducing interest expense. Martin Whitman would check industry trends.
31.39%
D&A growth above 1.5x AGEN's 1.81%. Michael Burry would check for excessive investment.
-52.58%
Both companies show EBITDA decline. Martin Whitman would check industry conditions.
-3087.14%
Both companies show margin pressure. Martin Whitman would check industry conditions.
-52.01%
Both companies show declining income. Martin Whitman would check industry conditions.
-3075.40%
Both companies show margin pressure. Martin Whitman would check industry conditions.
137.14%
Other expenses growth above 1.5x AGEN's 69.16%. Michael Burry would check for concerning trends.
-51.43%
Pre-tax income decline while AGEN shows 2.71% growth. Joel Greenblatt would examine position.
-3063.27%
Both companies show margin pressure. Martin Whitman would check industry conditions.
100.00%
Tax expense growth while AGEN reduces burden. John Neff would investigate differences.
-52.47%
Net income decline while AGEN shows 19.48% growth. Joel Greenblatt would examine position.
-3085.00%
Net margin decline while AGEN shows 0.18% growth. Joel Greenblatt would examine position.
-43.48%
EPS decline while AGEN shows 23.83% growth. Joel Greenblatt would examine position.
-43.48%
Diluted EPS decline while AGEN shows 24.85% growth. Joel Greenblatt would examine position.
7.17%
Share count reduction below 50% of AGEN's 5.86%. Michael Burry would check for concerns.
7.17%
Diluted share reduction below 50% of AGEN's 7.25%. Michael Burry would check for concerns.